Takeda wagers $300M on Protagonist’s PhIII rare disease drug

Amber Tong

Senior Editor

Takeda is lending Protagonist Therapeutics a hand in steering its lead rare disease drug to market, buying into its late-stage development and pending commercialization for $300 million upfront.

Protagonist has already begun a Phase III trial for the candidate, rusfertide, involving patients with a rare blood disorder called polycythemia vera (PV). The biotech will remain responsible for R&D through the completion of the study and US regulatory approval. And Takeda, which will “work closely” with Protagonist in this process, is responsible for future ex-US development and commercialization work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Takeda wagers $300M on Protagonist’s PhIII rare disease drug

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

House Oversight chair presses FDA on China amid growing tensions

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Take­da wa­gers $300M on Pro­tag­o­nist’s PhI­II rare dis­ease drug

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Benchling

San Francisco, CA, USA

Takeda wagers $300M on Protagonist’s PhIII rare disease drug